在老鼠模型 (APP/PS1) 中表征阿尔茨海默病的炎症调解者
Adrian Jorda1,2, Kenia Alvarez-Gamez1, Ignacio Campo-Palacio1
1Department of Physiology, School of Medicine, University of Valencia, 46010 València, Spain.
NeuroSci
|February 20, 2026
概括
这就是阿尔茨海默病的原因.
科学领域:
- 神经科学是一个神经科学.
- 免疫学 免疫学 免疫学
- 病理学 病理学 病理学
背景情况:
- 阿尔茨海默病 (AD) 病理包括粉样斑块,高酸化TAU和神经炎症.
- APP/PS1小鼠模型对于研究AD病变的发病过程至关重要.
- 化基因及其受体与阿尔茨海默病的复杂机制有关.
研究的目的:
- 为了研究雌性APP/PS1小鼠大脑皮层中特定化学和化学受体的表达.
- 探索这些分子在AD中中枢神经系统 (CNS) 中的神经炎症和免疫细胞相互作用中的作用.
主要方法:
- 西方斑点分析被用来评估化学激素受体表达.
- 用RT-PCR量化化基因和受体水平 (CCR6,CCR7,CCR10,CCL6,CCL8,CCL19,CCL20,CCL24,CCL27) 的结果.
- 分析了来自老年雌性APP/PS1小鼠和对照组的大脑皮层组织.
主要成果:
- 在APP/PS1小鼠中观察到CCL8和CCL19以及它们的受体的显著下降.
- 相反,CCL6,CCL24,CCL20,CCL27及其相应的受体显示出显著的增加.
- 特定的化学激素 (CCL8,CCL20) 和免疫细胞贩运者 (CCL19,CCL27) 呈现出改变的表达模式.
结论:
- 在APP/PS1小鼠中改变了化学基因表达,这表明在AD相关的神经炎症和免疫反应中发挥了作用.
- 像CCL24这样的化学因子可以作为早期AD检测和疾病监测的潜在生物标志物.
- 调节化基因通路为减少阿尔茨海默病中神经炎症的潜在治疗策略.
更多相关视频
08:01Intracerebroventricular Injection of Amyloid-β Peptides in Normal Mice to Acutely Induce Alzheimer-like Cognitive Deficits
Published on: March 16, 2016
44.6K
08:25Detecting Amyloid-β Accumulation via Immunofluorescent Staining in a Mouse Model of Alzheimer's Disease
Published on: April 19, 2021
4.1K
相关概念视频
Alzheimer's Disease: Overview
1.8K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.8K
Alzheimer's Disease: Treatment
1.1K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.1K
